Skip to main content

Texas Health and Human Services

Vendor Drug Program
  • Home
    • About the Program
    • Manuals
    • Contact Us
    • News
    • Providers
    • Pharmacy Search
    • Prescriber Search
    • Pharmacy Enrollment
    • Enrollment Forms
    • 340B Providers
    • Formulary
    • Formulary Search
    • Clinician-Administered Drugs
    • Clinical Prior Authorization - Traditional Medicaid
    • Clinical Prior Authorization - Managed Care
    • Preferred Drugs
    • Prior Authorization
    • Specialty Drugs
    • Synagis
    • Resources
    • Managed Care
    • Drug Utilization Review Board
    • Manufacturers
    • Downloads
    • Reports

Breadcrumb

  1. Home
  2. About
  3. Manuals
  4. Retrospective Drug Use Criteria Handbook
  5. C-4. Drug Use Criteria
  6. Acetylcholinesterase Inhibitors
  7. 1. Dosage

Retrospective Drug Use Criteria Handbook

  • Search this manual
  • C-1. About
  • C-2. Contact
  • C-3. Drug Use Compendia
  • C-4. Drug Use Criteria
    • Acetylcholinesterase Inhibitors
      • Introduction
      • 1. Dosage
        • 1.1. Adults
        • 1.2. Pediatrics
      • 2. Duration of Therapy
      • 3. Duplicative Therapy
      • 4. Drug-Drug Interactions
      • 5. References
    • Aerosolized Agents - metered-dose inhalers: anti-cholinergic drugs
    • Aerosolized Agents - metered-dose inhalers: anti-inflammatory drugs
    • Aerosolized Agents - metered-dose inhalers: beta2 adrenergic drugs (long-acting)
    • Aerosolized Agents - metered-dose inhalers: beta2 adrenergic drugs (short-acting)
    • Angiotensin II Receptor Blockers
    • Angiotensin-Converting Enzyme Inhibitors
    • Anti-depressants, oral (other)
    • Anti-depressants, selective serotonin reuptake inhibitors
    • Anti-diabetic Agents (oral)
    • Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder Medications
    • Atypical Anti-psychotics (long-acting injectable)
    • Atypical Anti-psychotics (oral)
    • Benzodiazepines (Oral, Nasal, Rectal)
    • Complement Inhibitor and Enzyme/Protein Replacement Therapy
    • Cyclooxygenase-2 Inhibitors
    • Direct Oral Anticoagulants
    • Exogenous Insulin Products
    • Fentanyl
    • Fluoroquinolones (oral)
    • Gabapentin
    • Glucagon-like Peptide 1 Receptor Agonists
    • Hepatitis C Direct-Acting Antivirals
    • Histamine H2 - Receptor Antagonists
    • Hydrocodone Bitartrate/Hydrocodone Polistirex
    • Hydroxy-Methylglutaryl Coenzyme A Reductase Inhibitors
    • Immune Globulins
    • Ivacaftor (Kalydeco) and Lumacaftor/Ivacaftor (Orkambi)
    • Ketorolac (oral)
    • Leukotriene Receptor Antagonists
    • Low-Molecular-Weight Heparins
    • Mecasermin
    • Memantine
    • Nebulized Bronchodilators
    • Nitazoxanide (Alinia)
    • Non-sedating Antihistamines
    • Non-steroidal anti-inflammatory drugs
    • Platelet Aggregation Inhibitors
    • Pramlintide
    • Promethazine Use In Children Less Than 2 Years of Age
    • Proton Pump Inhibitors
    • Quetiapine (low dose)
    • Rifaximin (Xifaxan)
    • Sedative/Hypnotics
    • Serotonin 5-HT1B/1D Receptor Agonists
    • Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting (oral)
    • Sickle Cell Disease Products
    • Skeletal Muscle Relaxants
    • Substance P/Neurokinin1 Receptor Antagonists
    • Topical Calcineurin Inhibitors
    • Tramadol
  • C-5. Revision History

1. Dosage

  • 1.1. Adults
  • 1.2. Pediatrics
  • Printer-friendly version
  • Texas.gov
  • Website Policy
  • Notice of Privacy Practices
  • Accessibility
  • Statewide Search
  • File-Viewing Information
  • Homeland Security
  • Compact with Texans
  • Contact Us
  • Report Fraud, Waste and Abuse

© Copyright 2014-2023. Texas Health & Human Services Commission. All rights reserved.